The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping andin vitro–in vivoextrapolation of drug clearance and drug-drug interaction potential

In vitroandin vivoglucuronidation of midazolam in humans

(2009) Ruth Hyland et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Methodological Uncertainty in Quantitative Prediction of Human Hepatic Clearance from In Vitro Experimental Systems

(2009) D. Hallifax et al.   CURRENT DRUG METABOLISM

Characterization of the Binding of Drugs to Human Intestinal Fatty Acid Binding Protein (IFABP): Potential Role of IFABP as an Alternative to Albumin for in Vitro-in Vivo Extrapolation of Drug Kinetic Parameters

(2009) A. Rowland et al.   DRUG METABOLISM AND DISPOSITION

Relative Importance of Intestinal and Hepatic Glucuronidation—Impact on the Prediction of Drug Clearance

(2009) Helen E. Cubitt et al.   PHARMACEUTICAL RESEARCH

The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan

(2008) Anna Alonen et al.   BIOCHEMICAL PHARMACOLOGY

Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction

(2008) S. Ohno et al.   DRUG METABOLISM AND DISPOSITION

Contribution of the N-Glucuronidation Pathway to the Overall in Vitro Metabolic Clearance of Midazolam in Humans

(2008) S. Klieber et al.   DRUG METABOLISM AND DISPOSITION

Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes

(2008) P. J. Kilford et al.   DRUG METABOLISM AND DISPOSITION

The "Albumin Effect" and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities

(2008) A. Rowland et al.   DRUG METABOLISM AND DISPOSITION

Dopamine Is a Low-Affinity and High-Specificity Substrate for the Human UDP-Glucuronosyltransferase 1A10

(2008) K. Itaaho et al.   DRUG METABOLISM AND DISPOSITION

The Configuration of the 17-Hydroxy Group Variably Influences the Glucuronidation of  -Estradiol and Epiestradiol by Human UDP-Glucuronosyltransferases

(2008) K. Itaaho et al.   DRUG METABOLISM AND DISPOSITION

Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants

(2008) M.-O. Benoit-Biancamano et al.   DRUG METABOLISM AND DISPOSITION

Regio- and Stereospecific N-Glucuronidation of Medetomidine: The Differences between UDP Glucuronosyltransferase (UGT) 1A4 and UGT2B10 Account for the Complex Kinetics of Human Liver Microsomes

(2008) S. Kaivosaari et al.   DRUG METABOLISM AND DISPOSITION

The "Albumin Effect" and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9

(2008) A. Rowland et al.   DRUG METABOLISM AND DISPOSITION

Effect of the β-glucuronidase inhibitor saccharolactone on glucuronidation by human tissue microsomes and recombinant UDP-glucuronosyltransferases

(2008) Lauren Oleson et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Kinetic Modeling of the Interactions between 4-Methylumbelliferone, 1-Naphthol, and Zidovudine Glucuronidation by UDP-Glucuronosyltransferase 2B7 (UGT2B7) Provides Evidence for Multiple Substrate Binding and Effector Sites

(2008) V. Uchaipichat et al.   MOLECULAR PHARMACOLOGY